SCHEMBL423699

SCHEMBL423699

O=C1[CH]CC(=O)N1S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5443341 0.67
SCHEMBL4698157 0.67
SCHEMBL8158051 0.67
SCHEMBL1491907 0.59
SCHEMBL16197017 0.58 NR1I2 (0.31)
Water SCHEMBL6096372 0.57 MGLL (0.42)
SCHEMBL1721131 0.55
SCHEMBL8724660 0.51
SCHEMBL7771362 0.50
SCHEMBL10767319 0.46

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948241-B1 MULTI-DRUG LIGAND CONJUGATES ENDOCYTE INC (US) 2014-03-05 EP claimed
US-7601332-B2 Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates ENDOCYTE, INC. (US) 2009-10-13 US claimed
US-20080248052-A1 Vitamin receptor binding drug delivery conjugate ENDOCYTE, INC. 2008-10-09 US claimed
EP-1948241-A2 MULTI-DRUG LIGAND CONJUGATES Endocyte, Inc. (US) 2008-07-30 EP claimed
WO-2007022494-A2 MULTI-DRUG LIGAND CONJUGATES ENDOCYTE, INC. (US) 2007-02-22 WO claimed
EP-1592457-A2 VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES Endocyte, Inc. (US) 2005-11-09 EP claimed
US-20050002942-A1 Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates ENDOCYTE, INC. 2005-01-06 US claimed
WO-2004069159-A2 VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES ENDOCYTE, INC. (US) 2004-08-19 WO claimed
EP-4337663-A2 SMALL MOLECULE-BASED BI-SPECIFIC IMMUNE CELL TETHERS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION Purdue Research Foundation (US) 2024-03-20 EP disclosed
US-20240058478-A1 FOLATE RECEPTOR-TARGETED CONJUGATES, COMPOSITIONS, AND DELIVERY TO THE CENTRAL NERVOUS SYSTEM PURDUE RESEARCH FOUNDATION 2024-02-22 US disclosed
US-20240002408-A1 FIBROBLAST ACTIVATION PROTEIN (FAP) - TARGETED ANTIFIBROTIC THERAPY PURDUE RESEARCH FOUNDATION 2024-01-04 US disclosed
US-20230390422-A1 OLIGONUCLEOTIDE-BASED THERAPEUTICS AND USES THEREOF SPEER TOD (US) 2023-12-07 US disclosed
EP-4274595-A1 FOLATE RECEPTOR-TARGETED CONJUGATES, COMPOSITIONS, AND DELIVERY TO THE CENTRAL NERVOUS SYSTEM Purdue Research Foundation (US) 2023-11-15 EP disclosed
US-20230346752-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION 2023-11-02 US disclosed
WO-2009002993-A1 CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS ENDOCYTE, INC. (US) 2008-12-31 WO disclosed
WO-2008112873-A2 BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS ENDOCYTE, INC. (US) 2008-09-18 WO disclosed
WO-2008101231-A2 METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE ENDOCYTE, INC. (US) 2008-08-21 WO disclosed
EP-1592457-A2 VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES Endocyte, Inc. (US) 2005-11-09 EP disclosed
US-20050002942-A1 Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates ENDOCYTE, INC. 2005-01-06 US disclosed
WO-2004069159-A2 VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES ENDOCYTE, INC. (US) 2004-08-19 WO disclosed